When the world quiets down at night, any little sound—like a creaky pipe, or a passing car—can seem earsplitting. But the solution to your less-than-silent nights may actually be more noise. “White noise machines decrease distraction by covering up noises that could keep you awake,” explains Carl Brazil, MD, the director of the Division of
0 Comments
February 8, 2016, by NCI Staff An obese mouse (left) and a mouse of normal weight (right). Credit: Wikimedia Commons Researchers have identified a biological mechanism that may help explain a longstanding association between obesity and an increased risk of colorectal cancer in humans. In mice, the researchers found, the excess intake of calories reduced
0 Comments
February 5, 2016, by NCI Staff Credit: National Cancer Institute Many women cancer survivors have problems with mobility and other physical functioning as a result of persistent peripheral neuropathy caused by chemotherapy treatment, according to a new study. The problems with physical functioning were associated with a substantial increase in the women’s risk for injurious
0 Comments
February 2, 2016, by NCI Staff Noel Brewer, Ph.D. Credit: UNC Lineberger Comprehensive Cancer Center Last week, all 69 NCI-Designated Cancer Centers released a consensus statement on human papillomavirus (HPV) vaccination in the United States. The statement describes the continued low rates of HPV vaccination as “a serious public health threat,” recommends that parents have their children
0 Comments
February 1, 2016, by Barbara Conley, M.D. In August 2015, NCI and the ECOG-ACRIN Cancer Research Group launched NCI-MATCH, the largest, first-of-its-kind precision medicine cancer clinical trial to date. As the trial has progressed, we felt it was a good time to bring the cancer community up to date on the status of NCI-MATCH and,
0 Comments
January 29, 2016, by NCI Staff Two types of gold nanoparticles spiked with spherical nucleic acids. Researchers are testing these nanoparticles as cancer therapies and diagnostic tools. Credit: National Cancer Institute NCI recently released the Cancer Nanotechnology Plan 2015. In this interview, Piotr Grodzinski, Ph.D., director of NCI’s Office of Cancer Nanotechnology Research, discusses the
0 Comments
January 28, 2016, by NCI Staff The Preparatory Education About Clinical Trials (PRE-ACT) program includes targeted video clips that address patients’ specific concerns and knowledge gaps. Credit: American Society of Clinical Oncology Educating patients with cancer about clinical trials prior to their first visit with their oncologist can improve their ability to make decisions about
0 Comments
January 25, 2016, by NCI Staff Mutant versions of the p53 tumor suppressor protein can clump together, stopping them from functioning. Treatment with ReACp53 can prevent this aggregation and restore p53’s function. Researchers have developed a new approach for treating tumors that express mutant versions of the p53 protein, which are present in more than
0 Comments
January 21, 2016, by Douglas R. Lowy, M.D. President Obama has tapped Vice President Biden to lead a major new cancer research initiative. Credit: The White House As many in the cancer community are aware by now, during his State of the Union address to Congress last week, President Obama gave a strong endorsement of Vice
0 Comments
January 19, 2016, by NCI Staff A dividing lung cancer cell. Credit: National Institutes of Health The Food and Drug Administration (FDA) approved alectinib (Alecensa®) on December 11, 2015, for some patients with metastatic non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The agency granted an accelerated approval for alectinib for patients whose cancer
0 Comments
January 15, 2016, by NCI Staff Acalabrutinib (ACP-196) targets BTK, a key switch in a signaling pathway required for the growth and survival of chronic lymphocytic leukemia cells. Credit: Adrian Wiestner, M.D., NHLBI Reports from two early-stage trials of new oral drugs provide hope for patients with high-risk chronic lymphocytic leukemia (CLL) that has returned
0 Comments
Signs of a toxic relationship are sometimes easy to spot—blatant infidelity or physical violence, for example. But there can often be more subtle signs that something’s just not right between you and your partner—or between you and a close friend, a coworker, or a family member. (It’s not just romantic relationships that can become toxic.)
0 Comments
January 12, 2016, by NCI Staff The genes PDGFRA and FIP1L1 are normally confined to separate loop domains (A) and rarely interact, but they can become closely associated (B) in tumors with IDH mutations. Credit: Broad Communications / Lauren Solomon Researchers studying brain tumors have identified a previously unknown genetic mechanism that may contribute to
0 Comments
January 6, 2016, by NCI Staff The FDA recently approved three new drugs to treat multiple myeloma. One of the drugs is the first approved cancer therapy to target the CD38 protein (pictured). Credit: Wikimedia Commons / Emw, CC-BY-SA-3.0 The Food and Drug Administration (FDA) has approved three new drugs for the treatment of multiple myeloma
0 Comments
December 28, 2015, by NCI Staff Last month, the FDA approved two drugs that inhibit the activity of the epidermal growth factor receptor, or EGFR, for the treatment of patients with advanced lung cancer. Credit: Wikimedia Commons Last month, the Food and Drug Administration (FDA) approved two targeted therapies for patients with advanced non-small cell
0 Comments
December 23, 2015, by NCI Staff A new study highlights the importance of discussions between patients and their physicians about the costs of cancer care. Credit: iStock In a survey of cancer survivors, many reported having experienced financial difficulties—such as going into debt, filing for bankruptcy, and consistent worry about financial issues—related to their disease
0 Comments
December 22, 2015, by NCI Staff NCI’s SEER program recently released the newest installment in its Did You Know video series. Many other new resources are available from NCI. NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community. Email Subscription Service
0 Comments
December 18, 2015, by NCI Staff NCI’s Dr. James Gulley (left) talks with his patient being treated at the NIH Clinical Center. Credit: NIH Intramural Research Program Earlier this year, former U.S. President Jimmy Carter announced that he was undergoing treatment for advanced melanoma that included the immunotherapy drug pembrolizumab (Keytruda®)—part of a class of
0 Comments
December 17, 2015, by NCI Staff Image of neuroblastoma cells, the most common solid cancer found in children younger than age 5. Credit: The Cell Image Library / CC BY 3.0 An international team of scientists has identified a possible new treatment target for pediatric neuroblastoma. Based on promising findings in animal models, the team
0 Comments
December 15, 2015, by NCI Staff Cobimetinib inhibits the activity of an enzyme known as MEK and vemurafenib inhibits the enzyme BRAF to disrupt cancer cell growth and survival. Credit: Cisbio Bioassays On November 10, the Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic™) in combination with vemurafenib (Zelboraf®) to treat patients
0 Comments
When walking you need your shoes to handle that repetitive heel-to-toe rolling motion. After all, “a 150-pound woman’s body encounters between 900,000 and 1,350,00 pounds of impact over a three-mile walk,” says Paul Langer, DPM, author of Great Feet for Life. So make sure your kicks are comfy and supportive—a poor fit can lead to
0 Comments
  With 2016 on the horizon, that means another 365 days to get your sweat on (minus a few rest and recovery days, of course). Curious what trends are on tap? Here are the top five (and then some) according to the American College of Sports Medicine’s (ACSM) annual survey, which was completed by more than
0 Comments
December 4, 2015, by NCI Staff Soft tissue sarcoma forms in soft tissues of the body, including muscle, tendons, fat, blood vessels, lymph vessels, nerves, and tissue around joints. On October 23, the Food and Drug Administration (FDA) approved trabectedin (Yondelis®) for the treatment of two subtypes of soft tissue sarcomas: liposarcoma and leiomyosarcoma. The
0 Comments